Annexin Pharmaceuticals AB (publ) announced that the first patient with retinal vein occlusion (RVO) has been dosed in the Company's Phase 2 clinical study with ANXV.  RVO is one of the most common causes of blindness. Authorized drugs for treatment of RVO are injected directly into the eye and have no direct effect on the blockage of blood vessels that causes the disease. By contrast, the Company's drug candidate ANXV, which is administered intravenously, has the potential to directly counteract the blockage of blood vessels as well as the retinal swelling and the inflammatory processes caused by RVO.

The Phase 2 study is placebo-controlled and is expected to involve approximately 20 patients at five trial centers in the United States. The study will evaluate the safety and tolerability of ANXV and endpoints related to vision and retinal function. Initial safety data from the study are expected to be available at the end of 2022 and efficacy data during the first half of 2023.